Flori­da judge dis­miss­es Zan­tac can­cer claims against GSK, oth­er phar­mas

GSK can breathe a lit­tle eas­i­er af­ter a Flori­da fed­er­al judge dis­missed thou­sands of claims that Zan­tac and re­lat­ed heart­burn prod­ucts caused can­cer, trig­ger­ing a boost in pre­mar­ket trad­ing on Wednes­day.

Plain­tiffs in the sprawl­ing mul­ti­dis­trict lit­i­ga­tion (MDL) at first at­tempt­ed to link pop­u­lar ran­i­ti­dine heart­burn prod­ucts to 10 types of can­cer, but lat­er with­drew breast, kid­ney, col­orec­tal, prostate and lung. On Tues­day, Judge Robin Rosen­berg tossed the re­main­ing claims in liv­er, blad­der, pan­cre­at­ic, esophageal, and stom­ach can­cers, up­on de­ter­min­ing that the al­le­ga­tions were based on “flawed” and “un­re­li­able” ev­i­dence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.